Kindai University Faculty of Medicine Reports Findings in Osteoporosis (Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid …): Musculoskeletal Diseases and Conditions – Osteoporosis

2022 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Musculoskeletal Diseases and Conditions - Osteoporosis is the subject of a report. According to news reporting originating in Osaka, Japan, by NewsRx journalists, research stated, “Early initiation of anti-osteoporosis medications (AOMs) is recommended for patients on long-term glucocorticoid (GC) therapy. This study aimed to clarify the real-world effectiveness of AOMs against incident hip and vertebral fractures in patients undergoing GC therapy using the nationwide health insurance claims database of Japan (NDBJ).”

The news reporters obtained a quote from the research from the Kindai University Faculty of Medicine, “Patients aged 50 years who were prescribed GC ( 5 mg/day prednisolone or equivalent) for 90 days and who were followed up regarding AOM prescription and hip and clinical vertebral fracture incidences for the subsequent 1080 days between 2012 and 2018 were selected from NDBJ. Associations of AOMs prescribed within 90 days since GC therapy initiation with hip or vertebral fracture risk were evaluated by Cox proportional hazards regression using propensity score inverse probability weighting (IPW) for receiving any AOM or individual AOMs. In total, 96,475 women and 98,385 men were included in the analysis; 38.0 % of women and 27.6 % of men received AOMs. Patients who received any AOM and those who received bisphosphonates or denosumab had a significantly lower risk of hip and clinical vertebral fractures than those who received no AOM in both sexes after propensity score IPW. Teriparatide was associated with an increased risk of both fractures in women and an increased risk of clinical vertebral fractures in men. Selection biases such as confounding by indication might have caused an underestimation of AOMs’ protective effects.”

According to the news reporters, the research concluded: “Bisphosphonates and denosumab were associated with a lower fracture incidence in patients on long-term GC therapy in real-world settings.”

This research has been peer-reviewed.

For more information on this research see: Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan. Bone, 2022;166:116605. Bone can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA. (Elsevier - www.elsevier.com; Bone - http://www.journals.elsevier.com/bone/)

Our news correspondents report that additional information may be obtained by contacting Masayuki Iki, Dept. of Public Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Additional authors for this research include Kenji Fujimori, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Nobukazu Okimoto, Kuniyasu Kamiya and Sumito Ogawa.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.bone.2022.116605. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher of the journal Bone can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)